Developer docs
API playgroundTry for free, no card

Search company profiles

KSILINK

Full company profile

uuid0026ctd

Namestring
KSILINK
Legal namestring
Ksilink
Websiteurl
ksilink.com
Company typeenum
Private
Founded yearint
2014
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersStrasbourg, France
HQ citystring
Strasbourg
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
phenotypic drug discovery, patient-derived disease models, high-content cellular screening, AI image analysis, target identification services
Industry6 codes
PRIMARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAIAG
CRISPR & Functional Genomics Screening Platforms (pooled/arrayed screens, perturb-seq)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAK
In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Drug Discovery Services
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Drug Discovery Partnerships
TypeProfessional Services
Description

Ksilink generates revenue through research collaborations and service contracts with pharmaceutical companies, biotech firms, and academic institutions. They offer assay development, screening services, and co-development programs.

ksilink.com
2Spin-off Companies
TypeLicensing Royalties
Description

Ksilink creates spin-off companies from successful programs, such as Myrtil Biotechnologies for dilated cardiomyopathies, generating value through equity or licensing arrangements.

ksilink.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

KSILINK designs and applies patient-derived and genome-edited cellular disease models for large-scale phenotypic drug discovery. It offers assay development, target identification, high-content phenotypic screening (using siRNA, CRISPR, and small molecule libraries), and AI-powered image and data analysis services to pharmaceutical, biotech, and academic partners. Its proprietary engine combines AI-boosted cellular profiling with patient-derived cellular systems to identify druggable targets and progress compounds toward clinical validation.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Successfully generated phenotypic profiles for patient-derived neurons that can classify disease vs healthy state with high accuracy
+3 more records
Product overview1 text field

KSILINK operates as a patient-based drug discovery platform offering a suite of services centered around its proprietary AI-boosted cellular profiling technologies. The core offering includes patient-based cellular disease models and assay development services for large-scale phenotypic screening, complemented by AI-powered image and data analysis services. The company provides end-to-end capabilities spanning assay development, target identification, screening solutions, and data science. In 2022, KSILINK established Myrtil Biotechnologies as a spin-off with myriamed GmbH to commercialize AI-powered dilated cardiomyopathy screening programs.

Product and service5 records
1Patient-Based Drug Discovery Services
CategoryDrug discovery services
Description

Comprehensive drug discovery services using patient-derived cellular disease models and complex cellular systems for large-scale phenotypic screening, supporting partners, customers, and in-house programs.

2Assay Development Services
CategoryDrug discovery services
Description

Development of primary and secondary phenotypic assays using complex human disease models, with focus on robustness and high-throughput scalability for large-scale phenotypic screening campaigns.

3Screening Solutions
CategoryDrug discovery services
Description

Large-scale phenotypic screening campaigns using siRNA, CRISPR, or small molecular compound libraries with high-content phenotypic readouts from microscopic imaging.

4Data Science Services
CategoryDrug discovery services
Description

AI-powered image and data analysis services, including tailored analysis tools developed by the KSILINK team for disease-specific applications.

5Myrtil Biotechnologies Spin-off Program
CategoryDrug discovery programs / spin-off
Description

Joint spin-off program with myriamed GmbH that conducts large-scale screening campaigns in dilated cardiomyopathies to identify new mechanisms of action, targets, and therapeutic molecules, generating value through equity and licensing arrangements.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership14 partners
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-02-23
Description

Oncodesign Precision Medicine and Ksilink join forces to test the Nanocyclix® chemical library in cell models derived from patients with serious central nervous system diseases, expanding Ksilink's CNS drug discovery capabilities

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-08-29
Description

Collaboration using patient-derived cellular model for Parkinson's Disease based on SNCA triplication to identify and rescue phenotypes through morphological profiling

3University of Chieti
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-12-11
Description

Collaboration with researchers from University of Chieti in Italy on study of effects of Endocrine Disrupting Chemicals on human stem cell-derived neurons for Parkinson's disease research

ksilink.com
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2023-05-25
Description

EIC Pathfinder consortium on Cardiogenomics meets AI for arrhythmogenic cardiomyopathy diagnosis and treatment. Ksilink contributes phenotypic and functional profiling of cardiac muscle disorders as partner of 7-member consortium

5EnvironMENTAL Consortium
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2022-09-07
Description

EC-funded consortium coordinated by Charité Hospital focused on identifying molecular and neural mechanisms of environmentally-induced mental illness, with 20+ partners including Ksilink as SME

ksilink.com
6Myrtil Biotechnologies
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2022-07-07
Description

Joint spin-off with myriamed GmbH based on AI-powered screenable disease model for dilated cardiomyopathies. Myrtil will conduct large-scale screening to identify new MOAs, targets and therapeutic molecules

ksilink.com
7JUMP-Cell Painting Consortium (Broad Institute)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-07-15
Description

Ksilink joined consortium of 10 pharmaceutical companies, 6 technology companies, and 2 non-profit partners coordinated by Broad Institute to create largest cell-imaging dataset with 140,000+ perturbations

ksilink.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-10-29
Description

Strategic partnership with myriamed GmbH (spinoff of University Medical Center Göttingen) to discover new active pharmaceutical ingredients for treating heart muscle diseases, leading to Myrtil Biotechnologies spin-off

9Biological Adaptation and Ageing (B2A-IBPS) / Sorbonne University
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-10-29
Description

Strategic partnership with research unit of Institute of Biology Paris Seine (Sorbonne Université/CNRS/Inserm) to discover new APIs for heart muscle diseases

ksilink.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-02-05
Description

Ksilink initiates drug discovery programs on Muscular Dystrophy-1 (DM1) and Autism Spectrum Disorders (ASD) with strategic partner I-Stem in Paris. Collaboration focuses on patient-based disease modeling and phenotypic screening.

11Luxembourg Centre for Systems Biomedicine (LCSB)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-06-18
Description

Ksilink teams up with LCSB of University of Luxembourg to develop drugs for Parkinson's disease using novel patient-based cell culture models with AI-powered automated testing of drug candidates

ksilink.com
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2016-06-08
Description

Sanofi and Ksilink entered research collaboration to accelerate discovery of next-generation therapies addressing unmet medical needs for Parkinson's disease patients, with Life & Brain contributing stem cell technologies

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2016-02-02
Description

Collaborative research agreement to apply stem-cell derived disease models of Duchenne Muscular Dystrophy to small molecule therapies discovery and development. Anagenesis achieved €3M seed funding subsequently

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2015-09-08
Description

Alliance to develop stem cell-based drug discovery approach for neurodegenerative diseases. Life & Brain provides stem cell technologies enabling disease modeling from patients.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Owkin applies AI to biomedical data including patient-derived multimodal datasets to accelerate drug discovery, partially overlapping with Ksilink's AI/biology intersection though more focused on data federation and clinical prediction.

TypeDirect peer
Description

Insitro combines machine learning with patient-derived cellular disease models to discover novel therapeutics, closely mirroring Ksilink's patient-based, AI-enabled phenotypic drug discovery model.

TypeDirect peer
Description

Cellarity develops medicines by targeting cellular behaviors rather than single molecular targets, using AI on cell-based phenotypic data—a near-direct analog to Ksilink's patient-based cellular profiling platform.

TypeDirect peer
Description

Exscientia is an AI-native pharma combining computational design with phenotypic assays and patient-derived cells, operating in the same AI-enabled drug discovery category as Ksilink with multiple pharma partnerships.

TypeBroad incumbent
Description

Evotec is a global contract research organization offering phenotypic screening, patient-derived disease models, and integrated drug discovery services to pharma, overlapping with Ksilink's discovery CRO activities but at much larger scale.

TypeEmerging player
Description

Cyclica is an AI-driven drug discovery company using proteome-wide and phenomic approaches to characterize drug candidates, comparable to Ksilink's AI-enabled, mechanism-agnostic profiling approach.

TypeBroad incumbent
Description

Eurofins Discovery is a large CRO offering in vitro pharmacology, phenotypic screening, and integrated drug discovery services, competing with Ksilink for pharma service contracts across Europe and globally.

TypeBroad incumbent
Description

Charles River is a major CRO providing phenotypic screening, cell-based assays, and drug discovery services across multiple therapeutic areas, making it a broad incumbent comparable to Ksilink's service offerings.

TypeDirect peer
Description

Recursion is a clinical-stage AI-driven drug discovery company using high-throughput phenotypic screening and machine learning on cellular imagery, directly overlapping with Ksilink's AI-boosted cellular profiling and target-agnostic discovery approach.

TypeEmerging player
Description

CytoReason builds AI models of human cell biology and disease for pharma R&D, sharing Ksilink's emphasis on cellular-level AI to accelerate therapeutic discovery.

Market position
Strengths6 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

KSILINK

Drug Discovery Servicesksilink.com

KSILINK firmographics

Firmographics
Name
KSILINK
Legal name
Ksilink
Website
https://ksilink.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

KSILINK industry classification

Industry
Product category
Drug Discovery Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAIAG
CRISPR & Functional Genomics Screening Platforms (pooled/arrayed screens, perturb-seq)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAK
In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Phenotypic drug discovery
  • Patient-derived disease models
  • High-content cellular screening
  • AI image analysis
  • Target identification services

Where KSILINK is headquartered

Location

Headquarters

HQ city
Strasbourg
HQ country
France
HQ region
Europe

Offices1 record

Markets served

KSILINK business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

  1. Drug Discovery Partnerships: Ksilink generates revenue through research collaborations and service contracts with pharmaceutical companies, biotech firms, and academic institutions. They offer assay development, screening services, and co-development programs.
  2. Spin-off Companies: Ksilink creates spin-off companies from successful programs, such as Myrtil Biotechnologies for dilated cardiomyopathies, generating value through equity or licensing arrangements.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

KSILINK product offering

Product offering

Core offering

KSILINK designs and applies patient-derived and genome-edited cellular disease models for large-scale phenotypic drug discovery. It offers assay development, target identification, high-content phenotypic screening (using siRNA, CRISPR, and small molecule libraries), and AI-powered image and data analysis services to pharmaceutical, biotech, and academic partners. Its proprietary engine combines AI-boosted cellular profiling with patient-derived cellular systems to identify druggable targets and progress compounds toward clinical validation.

Product overview

KSILINK operates as a patient-based drug discovery platform offering a suite of services centered around its proprietary AI-boosted cellular profiling technologies. The core offering includes patient-based cellular disease models and assay development services for large-scale phenotypic screening, complemented by AI-powered image and data analysis services. The company provides end-to-end capabilities spanning assay development, target identification, screening solutions, and data science. In 2022, KSILINK established Myrtil Biotechnologies as a spin-off with myriamed GmbH to commercialize AI-powered dilated cardiomyopathy screening programs.

Differentiator

Problem solved

Functional benefit

Products and services

  • Patient-Based Drug Discovery Services Comprehensive drug discovery services using patient-derived cellular disease models and complex cellular systems for large-scale phenotypic screening, supporting partners, customers, and in-house programs.
  • Assay Development Services Development of primary and secondary phenotypic assays using complex human disease models, with focus on robustness and high-throughput scalability for large-scale phenotypic screening campaigns.
  • Screening Solutions Large-scale phenotypic screening campaigns using siRNA, CRISPR, or small molecular compound libraries with high-content phenotypic readouts from microscopic imaging.
  • Data Science Services AI-powered image and data analysis services, including tailored analysis tools developed by the KSILINK team for disease-specific applications.
  • Myrtil Biotechnologies Spin-off Program Joint spin-off program with myriamed GmbH that conducts large-scale screening campaigns in dilated cardiomyopathies to identify new mechanisms of action, targets, and therapeutic molecules, generating value through equity and licensing arrangements.

Quantifiable outcome

  • Successfully generated phenotypic profiles for patient-derived neurons that can classify disease vs healthy state with high accuracy
  • +3 more outcomes

Companies that use KSILINK

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

KSILINK technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature7 records

KSILINK partnerships and signals

Strategic signal

Partnerships

14 partnerships are on record, tiered major, core and minor.

  • Oncodesign Precision MedicinemajorStrategic or Co-development Partner · 23 February 2026Oncodesign Precision Medicine and Ksilink join forces to test the Nanocyclix® chemical library in cell models derived from patients with serious central nervous system diseases, expanding Ksilink's CNS drug discovery capabilities
  • University of LuxembourgcoreStrategic or Co-development Partner · 29 August 2025Collaboration using patient-derived cellular model for Parkinson's Disease based on SNCA triplication to identify and rescue phenotypes through morphological profiling
  • University of ChietiminorStrategic or Co-development Partner · 11 December 2023Collaboration with researchers from University of Chieti in Italy on study of effects of Endocrine Disrupting Chemicals on human stem cell-derived neurons for Parkinson's disease research
  • IMPACT ConsortiummajorStrategic or Co-development Partner · 25 May 2023EIC Pathfinder consortium on Cardiogenomics meets AI for arrhythmogenic cardiomyopathy diagnosis and treatment. Ksilink contributes phenotypic and functional profiling of cardiac muscle disorders as partner of 7-member consortium
  • EnvironMENTAL ConsortiummajorStrategic or Co-development Partner · 7 September 2022EC-funded consortium coordinated by Charité Hospital focused on identifying molecular and neural mechanisms of environmentally-induced mental illness, with 20+ partners including Ksilink as SME
  • Myrtil BiotechnologiesmajorStrategic or Co-development Partner · 7 July 2022Joint spin-off with myriamed GmbH based on AI-powered screenable disease model for dilated cardiomyopathies. Myrtil will conduct large-scale screening to identify new MOAs, targets and therapeutic molecules
  • JUMP-Cell Painting Consortium (Broad Institute)coreStrategic or Co-development Partner · 15 July 2020Ksilink joined consortium of 10 pharmaceutical companies, 6 technology companies, and 2 non-profit partners coordinated by Broad Institute to create largest cell-imaging dataset with 140,000+ perturbations
  • myriamed GmbHcoreStrategic or Co-development Partner · 29 October 2019Strategic partnership with myriamed GmbH (spinoff of University Medical Center Göttingen) to discover new active pharmaceutical ingredients for treating heart muscle diseases, leading to Myrtil Biotechnologies spin-off
  • Biological Adaptation and Ageing (B2A-IBPS) / Sorbonne UniversitycoreStrategic or Co-development Partner · 29 October 2019Strategic partnership with research unit of Institute of Biology Paris Seine (Sorbonne Université/CNRS/Inserm) to discover new APIs for heart muscle diseases
  • I-StemcoreStrategic or Co-development Partner · 5 February 2019Ksilink initiates drug discovery programs on Muscular Dystrophy-1 (DM1) and Autism Spectrum Disorders (ASD) with strategic partner I-Stem in Paris. Collaboration focuses on patient-based disease modeling and phenotypic screening.
  • Luxembourg Centre for Systems Biomedicine (LCSB)coreStrategic or Co-development Partner · 18 June 2018Ksilink teams up with LCSB of University of Luxembourg to develop drugs for Parkinson's disease using novel patient-based cell culture models with AI-powered automated testing of drug candidates
  • SanofimajorStrategic or Co-development Partner · 8 June 2016Sanofi and Ksilink entered research collaboration to accelerate discovery of next-generation therapies addressing unmet medical needs for Parkinson's disease patients, with Life & Brain contributing stem cell technologies
  • Anagenesis BiotechnologiescoreStrategic or Co-development Partner · 2 February 2016Collaborative research agreement to apply stem-cell derived disease models of Duchenne Muscular Dystrophy to small molecule therapies discovery and development. Anagenesis achieved €3M seed funding subsequently
  • University of Bonn / Life & Brain GmbHcoreStrategic or Co-development Partner · 8 September 2015Alliance to develop stem cell-based drug discovery approach for neurodegenerative diseases. Life & Brain provides stem cell technologies enabling disease modeling from patients.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

KSILINK competitors and assessment

Company assessment

Emerging players

  • Owkin: Owkin applies AI to biomedical data including patient-derived multimodal datasets to accelerate drug discovery, partially overlapping with Ksilink's AI/biology intersection though more focused on data federation and clinical prediction.
  • Cyclica: Cyclica is an AI-driven drug discovery company using proteome-wide and phenomic approaches to characterize drug candidates, comparable to Ksilink's AI-enabled, mechanism-agnostic profiling approach.
  • CytoReason: CytoReason builds AI models of human cell biology and disease for pharma R&D, sharing Ksilink's emphasis on cellular-level AI to accelerate therapeutic discovery.

Direct peers

  • Insitro: Insitro combines machine learning with patient-derived cellular disease models to discover novel therapeutics, closely mirroring Ksilink's patient-based, AI-enabled phenotypic drug discovery model.
  • Cellarity: Cellarity develops medicines by targeting cellular behaviors rather than single molecular targets, using AI on cell-based phenotypic data—a near-direct analog to Ksilink's patient-based cellular profiling platform.
  • Exscientia: Exscientia is an AI-native pharma combining computational design with phenotypic assays and patient-derived cells, operating in the same AI-enabled drug discovery category as Ksilink with multiple pharma partnerships.
  • Recursion Pharmaceuticals: Recursion is a clinical-stage AI-driven drug discovery company using high-throughput phenotypic screening and machine learning on cellular imagery, directly overlapping with Ksilink's AI-boosted cellular profiling and target-agnostic discovery approach.

Broad incumbents

  • Evotec: Evotec is a global contract research organization offering phenotypic screening, patient-derived disease models, and integrated drug discovery services to pharma, overlapping with Ksilink's discovery CRO activities but at much larger scale.
  • Eurofins Discovery: Eurofins Discovery is a large CRO offering in vitro pharmacology, phenotypic screening, and integrated drug discovery services, competing with Ksilink for pharma service contracts across Europe and globally.
  • Charles River Laboratories: Charles River is a major CRO providing phenotypic screening, cell-based assays, and drug discovery services across multiple therapeutic areas, making it a broad incumbent comparable to Ksilink's service offerings.

Market position

Strengths6 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

KSILINK social profiles

Digital presence

KSILINK financial estimates

Financial estimate

Revenue estimate

Valuation estimate

KSILINK leadership team

Management profile

Number of profiles

Profiles8 records

KSILINK subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

KSILINK funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

KSILINK M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about KSILINK

What does KSILINK do?

KSILINK designs and applies patient-derived and genome-edited cellular disease models for large-scale phenotypic drug discovery. It offers assay development, target identification, high-content phenotypic screening (using siRNA, CRISPR, and small molecule libraries), and AI-powered image and data analysis services to pharmaceutical, biotech, and academic partners. Its proprietary engine combines AI-boosted cellular profiling with patient-derived cellular systems to identify druggable targets and progress compounds toward clinical validation.

Is KSILINK a public or private company?

KSILINK is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was KSILINK founded?

KSILINK was founded in 2014. It employs 11 to 50 people.

Where is KSILINK based?

KSILINK is headquartered in Strasbourg, France, in the Europe region.

How does KSILINK make money?

Two revenue lines are on record. Drug Discovery Partnerships are the primary driver. The others are spin-off Companies.

Who are KSILINK's main competitors?

Emerging players on record are Owkin, Cyclica and CytoReason. Direct peers are Insitro, Cellarity, Exscientia and Recursion Pharmaceuticals. Broad incumbents are Evotec, Eurofins Discovery and Charles River Laboratories.

Does KSILINK have an API?

No public API is recorded for KSILINK.

What industry is KSILINK in?

KSILINK's product category is Drug Discovery Services. Its primary akta.pro industry code is HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation), with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales